Table 2.
Primary and secondary endpoints of the ESCAPE trial
| Anakinra (n = 60) | Tocilizumab (n = 42) | OR (95% CI) | p value | |
|---|---|---|---|---|
| Primary endpoint, n (%) (95% CI) | 35 (58.3; 44.9–70.7) | 14 (33.3; 20.0–49.6) | 2.80 (1.23–6.37) | 0.02 |
| At least 25% decrease of baseline SOFA score by day 8 | 23 (38.3; 26.4–51.8) | 7 (16.7; 7.5–32.0) | 3.11 (1.19–8.15) | 0.03 |
| At least 50% increase of the baseline PaO2/FiO2 ratio by day 8 | 18 (30.0; 19.2–43.4) | 12 (28.6; 16.2–44.8) | 1.07 (0.45–2.55) | 1.00 |
| 28-day mortality, n (%) (95% CI) | 20 (33.3; 22.0–46.8) | 14 (33.3; 20.0–49.6) | 1.00 (0.43–2.31) | 1.00 |
| Delta SOFA day 28, median (Q1-Q3) | −10.0 (−75 to 257) | 0 (−55 to 440) | NA | 0.32 |
CI, confidence interval; NA, nonapplicable; OR, odds ratio; Q, quartile; SOFA, Sequential Organ Failure Assessment Score. Bold text indicates significance at 0.05 level.